Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis

International Journal of Antimicrobial Agents
A J BrinkGauteng Understanding Teicoplanin Serum levels (GUTS) study group

Abstract

The optimum teicoplanin loading dose and duration of therapy required for rapid attainment of a therapeutic trough plasma concentration (C(min)) (> or = 10mg/L for serious Gram-positive infections and > or = 20mg/L for deep-seated infections) are not known. In this open-label, multicentre, observational study, teicoplanin levels were determined following administration of loading doses of 6 mg/kg every 12h on Day 1 followed by 6 mg/kg once or twice daily to hospitalised patients with suspected or diagnosed Gram-positive infections. C(min) levels for the first 4 days of treatment were collected 15min prior to drug administration. Levels were determined with an Abbott TDx/FLx Analyzer and Seradyn Teicoplanin Innofluor Assay Kit. The two target trough values (> or = 10mg/L and > or = 20mg/L) were only achieved by Day 4 in the once-daily group (n=34; mean 9.55 mg/L, 95% confidence interval (CI) 8.17-10.94 mg/L) and in the twice-daily group (n=40; mean 21.8 mg/L, 95% CI 17.21-26.39 mg/L), respectively. However, the mean C(min) in the twice-daily group was > or = 10mg/L (11.03 mg/L) by Day 2. To achieve rapid therapeutic C(min) concentrations targeted for the majority of serious Gram-positive infections, we recommend teicoplanin load...Continue Reading

References

Aug 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J L Schmit
Apr 1, 1990·The Journal of Antimicrobial Chemotherapy·J S CheesbroughJ M Davies
Aug 6, 2002·The Journal of Antimicrobial Chemotherapy·Michael Weinbren, Keith Struthers
Jan 20, 2004·The Journal of Antimicrobial Chemotherapy·Mark WilcoxMatthew Dryden
Oct 25, 2006·Archives of Internal Medicine·Levita K HidayatAnnie Wong-Beringer
May 20, 2008·International Journal of Antimicrobial Agents·Ian M Gould

❮ Previous
Next ❯

Citations

Sep 21, 2013·Intensive Care Medicine·Andrew A UdyJeffrey Lipman
Sep 10, 2013·The Journal of Infection·Philippa C MatthewsMatthew Scarborough
Jul 15, 2009·Antimicrobial Agents and Chemotherapy·Shuli SvetitskyMical Paul
Dec 17, 2009·Clinical Pharmacokinetics·Andrew A UdyJeffrey Lipman
Dec 15, 2010·Clinical Pharmacokinetics·Marta UlldemolinsJeffrey Lipman
Dec 11, 2013·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Emmanuelle MercierLaurent Vecellio
Dec 15, 2015·Expert Opinion on Drug Metabolism & Toxicology·Sherwin K B SyHartmut Derendorf
Jul 24, 2012·International Journal of Antimicrobial Agents·Takaaki YamadaRyozo Oishi
Aug 13, 2011·British Journal of Clinical Pharmacology·Jason A RobertsJennifer H Martin
Jan 28, 2014·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Takashi UedaHiroki Ikeuchi
Dec 3, 2014·International Journal of Antimicrobial Agents·Yoichi HirakiYoshiharu Karube
Jun 10, 2016·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·T UedaT Kimura
Mar 8, 2017·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·C J ByrneJ McHugh
Sep 1, 2011·Einstein·Diogo Diniz Gomes BuganoEliézer Silva
Nov 3, 2016·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Ryo KobayashiToshiaki Sudoh
Jun 18, 2010·The Cochrane Database of Systematic Reviews·Alexandre B CavalcantiEliezer Silva
Oct 9, 2012·Current Opinion in Infectious Diseases·Brett Janson, Karin Thursky
Aug 17, 2011·Current Opinion in Infectious Diseases·Sebastiaan J van Hal, David L Paterson
Jul 1, 2011·The Korean Journal of Internal Medicine·Dong-Gun LeeJung-Hyun Choi
Nov 26, 2013·Therapeutic Drug Monitoring·Kazutaka OdaYusuke Takeshita
Apr 6, 2013·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Hiromi YanagimotoToshio Oguchi
Aug 14, 2010·Analytical Chemistry·Linliang YuYinan Wei

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.